Acute myocardial infarction therapy using calycosin and tanshinone co-loaded; mitochondrion-targeted tetrapeptide and cyclic arginyl-glycyl-aspartic acid peptide co-modified lipid-polymer hybrid nano-system: preparation, characterization, and anti myocardial infarction activity assessment.

Yan J, Guo J, Wang Y, Xing X, Zhang X, Zhang G, Dong Z

Drug delivery1 Dec 2022Cited by 11 (Europe PMC)

PMID36047255PMCIDPMC9487946DOI10.1080/10717544.2022.2118401PepBankPUB-36047255

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Pharmacokinetics
The MTP/RGD-CAL/TAN nano-system had an AUC of 178.86 ± 6.62 μg·min/mL.
In plain wordsA multi-ingredient nanoparticle containing an elamipretide-type peptide had an AUC of about 178.86 μg·min/mL in blood.
Peptide
Elamipretide (SS-31)
Outcome
Not applicableArea under the curve (AUC)
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Measurements
AUC
178.86 μg·min/mL
MTP/RGD-CAL/TAN NS
Source sentences
Summary
The area under the curve (AUC) and blood circulation half-life (T_1/2) of MTP/RGD-CAL/TAN NS was 178.86 ± 6.62 μg·min/mL and 0.47 h, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
MTP-131 was conjugated with PEG and modified onto the nanoparticles to achieve dual ligands co-modified MTP/RGD-CAL/TAN NS.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3604725503
02AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Pharmacokinetics
The MTP/RGD-CAL/TAN nano-system had a blood circulation half-life of 0.47 h.
In plain wordsA multi-ingredient nanoparticle containing an elamipretide-type peptide had a blood half-life of 0.47 hours.
Peptide
Elamipretide (SS-31)
Outcome
Not applicableBlood circulation half-life
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Measurements
blood circulation half-life
0.47 h
MTP/RGD-CAL/TAN NS
Source sentences
Summary
The area under the curve (AUC) and blood circulation half-life (T_1/2) of MTP/RGD-CAL/TAN NS was 178.86 ± 6.62 μg·min/mL and 0.47 h, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
MTP-131 was conjugated with PEG and modified onto the nanoparticles to achieve dual ligands co-modified MTP/RGD-CAL/TAN NS.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3604725504
03AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In rats with acute myocardial infarction, the MTP/RGD-CAL/TAN nano-system gave the most significant infarct size reduction, 22.9%.
In plain wordsIn rats with heart attack, a multi-ingredient nanoparticle reduced infarct size the most, by 22.9%.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseInfarct size reduction
Study
ratn: not reported in source
rat acute myocardial infarction model
Outcome group
Heart function · Cardiovascular
Measurements
infarct size reduction
22.9%
MTP/RGD-CAL/TAN NS
Source sentences
Summary
MTP/RGD-CAL/TAN NS exhibited the most significant infarct size reduction effect of 22.9%.
2 context sentences(design, population, supporting numbers)
Summary · context
The AMI therapy ability of the systems was investigated in AMI rats' model.
Summary · context
MTP-131 was conjugated with PEG and modified onto the nanoparticles to achieve dual ligands co-modified MTP/RGD-CAL/TAN NS.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3604725505
04AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Pharmacokinetics
In rats with acute myocardial infarction, the MTP/RGD-CAL/TAN nano-system showed the highest heart accumulation.
In plain wordsIn rats with heart attack, a multi-ingredient nanoparticle reached the heart more than the other tested systems.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseHeart accumulation
Study
ratn: not reported in source
rat acute myocardial infarction model
Outcome group
Pharmacokinetics · Cardiovascular
Source sentences
Summary
MTP/RGD-CAL/TAN NS exhibited the highest heart accumulation
2 context sentences(design, population, supporting numbers)
Summary · context
The AMI therapy ability of the systems was investigated in AMI rats' model.
Summary · context
MTP-131 was conjugated with PEG and modified onto the nanoparticles to achieve dual ligands co-modified MTP/RGD-CAL/TAN NS.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3604725506
05LabNot a test of Elamipretide (SS-31) aloneIn vitro (cell-free)Other
The MTP/RGD-CAL/TAN nano-system, which carries MTP-131 with calycosin and tanshinone, had a particle size of 170.2 ± 5.6 nm.
In plain wordsIn lab tests, the multi-ingredient nanoparticle had a size of 170.2 nm.
Peptide
Elamipretide (SS-31)
Outcome
Not applicableParticle size of the nano-system
Study
n: not reported in source
Outcome group
Formulation, delivery and stability · Pharmacology
Measurements
particle size
170.2 nm
MTP/RGD-CAL/TAN NS
Source sentences
Summary
The size of MTP/RGD-CAL/TAN NS was 170.2 ± 5.6 nm, with a surface charge of -18.9 ± 1.9 mV.
1 context sentence(design, population, supporting numbers)
Summary · context
MTP-131 was conjugated with PEG and modified onto the nanoparticles to achieve dual ligands co-modified MTP/RGD-CAL/TAN NS.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3604725501
06LabNot a test of Elamipretide (SS-31) aloneIn vitro (cell-free)Other
The MTP/RGD-CAL/TAN nano-system had a surface charge of -18.9 ± 1.9 mV.
In plain wordsIn lab tests, the multi-ingredient nanoparticle had a surface charge of about -18.9 mV.
Peptide
Elamipretide (SS-31)
Outcome
Not applicableSurface charge of the nano-system
Study
n: not reported in source
Outcome group
Formulation, delivery and stability · Pharmacology
Measurements
surface charge
−18.9 mV
MTP/RGD-CAL/TAN NS
Source sentences
Summary
The size of MTP/RGD-CAL/TAN NS was 170.2 ± 5.6 nm, with a surface charge of -18.9 ± 1.9 mV.
1 context sentence(design, population, supporting numbers)
Summary · context
MTP-131 was conjugated with PEG and modified onto the nanoparticles to achieve dual ligands co-modified MTP/RGD-CAL/TAN NS.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3604725502

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.